Published in Oncol Lett on June 10, 2015
Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol (1982) 43.81
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol (1997) 29.02
Reporting results of cancer treatment. Cancer (1981) 28.83
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med (2011) 24.32
One-sample multiple testing procedure for phase II clinical trials. Biometrics (1982) 6.45
Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol (2006) 4.70
Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol (2002) 4.15
Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer (2008) 3.19
Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol (2010) 2.69
Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer (1996) 2.23
Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res (1996) 1.74
Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol (1995) 1.49
cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep (1980) 1.47
Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J Clin Oncol (2002) 1.39
Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? (Review). Oncol Rep (2010) 1.38
Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J Clin Oncol (1999) 1.29
Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer (2001) 1.24
Gemcitabine: progress in the treatment of pancreatic cancer. Oncology (2001) 1.24
Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC). Br J Cancer (2005) 1.18
Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol (2002) 1.18
Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Ann Oncol (2000) 1.17
Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for Pancreatic Cancer. Ann Oncol (2001) 1.03
Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer. J Clin Oncol (2003) 1.00
Salvage chemotherapy with mitomycin, docetaxel, and irinotecan (MDI regimen) in metastatic pancreatic adenocarcinoma: a phase I and II trial. Cancer Invest (2004) 0.99
Preclinical combination therapy with gemcitabine and mechanisms of resistance. Semin Oncol (1996) 0.93
Activity of cisplatin in adenocarcinoma of the pancreas. Eur J Cancer (1993) 0.91
Phase II study of gemcitabine in combination with docetaxel in patients with advanced pancreatic carcinoma (E1298). A trial of the eastern cooperative oncology group. Oncology (2004) 0.88
A phase II trial of gemcitabine in combination with 5-fluorouracil (24-hour) and folinic acid in patients with chemonaive advanced pancreatic cancer. Ann Oncol (2000) 0.82
Biweekly triple combination chemotherapy with gemcitabine, oxaliplatin, levofolinic acid and 5-fluorouracil (GOLF) is a safe and active treatment for patients with inoperable pancreatic cancer. J Chemother (2008) 0.79
Phase II study of cisplatin, gemcitabine and 5-fluorouracil in advanced pancreatic cancer. Ann Oncol (2004) 0.78
Gemcitabine in advanced pancreatic cancer: a phase II trial. Am J Clin Oncol (2001) 0.76